Skip to main content

Table 1 Patients characteristics

From: Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?

Characteristic

Patients (%)

Median age (years)

40 years (range: 22–63 )

Gender

 

Male

9 (64%)

Female

5 (36%)

Histology

 

Osteoblastic osteosarcoma

1 (7%)

Chondroblastic osteosarcoma

10 (71%)

Fibroblastic

2 (15%)

Others

1 (7%)

Radiation induced sarcoma

2 (14%)

Median time to previous radiotherapy (years)

9 years (range: 6–12)

Primary site

 

Mandible

9 (64%)

Maxilla

5 (36%)

Preoperative chemotherapy regimen

 

MAP

9 (64%)

AP

5 (36%)

  1. MAP = methotrexate 12 g/m2, doxorubicin 75 mg/ m2, cisplatin 120 mg/m2.
  2. AP = doxorubicin 75 mg/ m2, cisplatin 100 mg/m2.